Cytiva, now with the life sciences business from Pall Corporation, is a global biotechnology leader dedicated to helping customers discover and commercialize the next generation of therapeutics. We bring dedicated technical expertise and a broad portfolio of tools, technologies, and services that enable the development, manufacture, and delivery of transformative medicines to patients. We're the provider of leading life science brands such as ÄKTA, Amersham, HyClone, MabSelect and Whatman. We are part of Danaher, a global science and technology leader. Along with other Danaher businesses, we accelerate the impact of tomorrow’s science and technology innovation to improve human health. Visit https://www.cytiva.com/privacy to review our privacy policy.
我們正在追蹤 Cytiva 的市場擴張
過去 90 日內有 132 個訊號。
Cytiva 的國際擴張與競爭對手的比較
Cytiva你長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 Cytiva你 | 0 | 0 | — | 0 | 0 |
Service Sales Development Manager EMEA West (m/f/d)
查看招聘Strasbourg, Grand Est, France · 前日
Service Sales Development Manager EMEA West (m/f/d)
查看招聘Marseille, Provence-Alpes-Côte d'Azur, France · 前日
Service Sales Development Manager EMEA West (m/f/d)
查看招聘Bordeaux, Nouvelle-Aquitaine, France · 前日
Meet Lars
進行中
Streamline your microbiology QC to cut rework, reduce paperwork, and move your release decisions faster
進行中
Accelerate product release with robust microbiology testing solutions
進行中外國製藥設備製造商開始拒絕向俄羅斯供應零件。德國公司Syntegon和GEA已暫停供應。其他公司如Sartorius和Cytiva已暫停接受訂單，但承諾會重返俄羅斯市場。
全球細胞培養市場預計將從2022年的209.6億美元增長到2030年的561.9億美元，這一增長由醫學和生物技術領域的研發增加所推動。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Cytiva 業務、市場及增長訊號的快速解答。
